P/B
0,6
Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
$7.9M
Market Cap • 10/9/2026
2015
(11 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
6,6
EPS
—
Market Cap
Market Cap
7,9M
EV
11,9M
EV/Revenue
2,5
EV/EBITDA
-0,4
EV/EBIT
-0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,4%
Total Yield
-0,4%
Payout
0%
Retained Earnings
-475,7M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
457,5%
Capex/Revenue
1,8%
Capex/D&A
9,2%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
43,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-15,5%
CAGR Net Income 5Y
-20,2%
CAGR EPS 5Y
-47,7%
CAGR OCF 5Y
-7,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,6
Quick Ratio
2,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!